Medical Radioisotope Application Group, Quantum Beam Science Directorate, Japan Atomic Energy Agency, Watanuki, Takasaki, Gunma 370-1292, Japan.
Nucl Med Biol. 2011 Aug;38(6):857-65. doi: 10.1016/j.nucmedbio.2011.02.001. Epub 2011 Apr 21.
3-[(18)F]fluoro-α-methyl-l-tyrosine ([(18)F]FAMT) is a useful amino acid tracer for positron emission tomography (PET) imaging of malignant tumors. FAMT analogs labeled with (76)Br, a positron emitter with a long half-life (t(1/2)=16.1 h), could potentially be widely used as amino acid tracers for tumor imaging. In this study, 3-[(76)Br]bromo-α-methyl-l-tyrosine ([(76)Br]BAMT) was designed, and its usefulness was evaluated as a novel PET tracer for imaging malignant tumors.
In this study, both [(76)Br]BAMT and [(77)Br]BAMT were prepared. The in vitro and in vivo stability of [(77)Br]BAMT was evaluated by HPLC analysis. Cellular uptake and retention of [(77)Br]BAMT and [(18)F]FAMT were evaluated using LS180 colon adenocarcinoma cells. Biodistribution studies were performed in normal mice and in LS180 tumor-bearing mice, and the tumors were imaged with a small-animal PET scanner.
[(77)Br]BAMT was stable in vitro but was catabolized after administration in mice. Cellular accumulation and retention of [(77)Br]BAMT were significantly higher than those of [(18)F]FAMT. In biodistribution studies, the tumor accumulation of [(77)Br]BAMT was higher than that of [(18)F]FAMT. However, some level of debromination was seen, which caused more retention of radioactivity in the blood and organs than was seen with [(18)F]FAMT. PET imaging with [(76)Br]BAMT enabled clear visualization of the tumor, and the whole-body image using [(76)Br]BAMT was similar to that using [(18)F]FAMT.
[(77)Br]BAMT showed high levels of tumor accumulation, and [(76)Br]BAMT enabled clear visualization of the tumor by PET imaging. Although an improvement in stability is still needed, (76)Br-labeled FAMT analogs could potentially serve as PET tracers for the imaging of malignant tumors.
3-[(18)F]氟-α-甲基-L-酪氨酸([(18)F]FAMT)是正电子发射断层扫描(PET)成像恶性肿瘤的有用氨基酸示踪剂。用半衰期长(t(1/2)=16.1 h)的正电子发射体(76)Br 标记的 FAMT 类似物可作为肿瘤成像的新型氨基酸示踪剂广泛应用。在这项研究中,设计了 3-[(76)Br]溴-α-甲基-L-酪氨酸([(76)Br]BAMT),并将其作为一种新型 PET 示踪剂用于恶性肿瘤成像的有效性进行了评估。
在这项研究中,制备了[(76)Br]BAMT 和[(77)Br]BAMT。通过 HPLC 分析评估[(77)Br]BAMT 的体外和体内稳定性。用 LS180 结肠腺癌细胞评估[(77)Br]BAMT 和[(18)F]FAMT 的细胞摄取和保留。在正常小鼠和 LS180 荷瘤小鼠中进行生物分布研究,并使用小动物 PET 扫描仪对肿瘤进行成像。
[(77)Br]BAMT 在体外稳定,但在小鼠体内给药后被代谢。[(77)Br]BAMT 的细胞积累和保留明显高于[(18)F]FAMT。在生物分布研究中,[(77)Br]BAMT 在肿瘤中的积累高于[(18)F]FAMT。然而,观察到一定程度的脱溴,这导致放射性在血液和器官中的保留水平高于[(18)F]FAMT。用[(76)Br]BAMT 进行 PET 成像可清晰显示肿瘤,并用[(76)Br]BAMT 进行全身成像与用[(18)F]FAMT 相似。
[(77)Br]BAMT 显示出高水平的肿瘤积累,并且[(76)Br]BAMT 可通过 PET 成像清晰显示肿瘤。尽管稳定性仍需改善,但(76)Br 标记的 FAMT 类似物有可能作为恶性肿瘤成像的 PET 示踪剂。